[ Pharmaceutical Sciences Asia - ONLINE ]
Print ISSN 2586-8195 E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

Pharm Sci Asia ; 32(2),
 

Alendronate, Raloxifene and Tibolone Inhibit the Proliferation-Stimulating Activity of 17-Estradiol in MCF-7 Cells

N. Sookvanichsilp* and C. Boonleang

-


Estrogen replacement therapy has been considered for many decades as the gold standard in the management of osteoporosis, but the risk of developing breast cancer outweighs its benefits. It is not known whether addition of another antiresorptive agent to estrogen replacement therapy will provide any beneficial effects against such risk. This in vitro study aimed to investigate the inhibitory effects of alendronate, raloxifene and tibolone on the proliferation-stimulating activity of 17-estradiol in MCF-7 cells. The effects of individual drugs, alendronate, raloxifene and tibolone, alone at concentrations of 10-10-10-4 M and their combinations with 10-8 M 17-estradiol on MCF-7 cell proliferation were determined on day 2 and day 6 of incubation using the standard tetrazolium MTT (cell viability) method. The cytotoxic effect of the drugs either alone or in combination with 17-estradiol was determined by visualizing morphological features of the MCF-7 cells and measuring the release of lactate dehydrogenase (LDH) from the cells. The results indicated that the three drugs inhibited the proliferation of MCF-7 cells in a concentration-related manner on both days of investigation. At all indicated concentrations, they could significantly inhibit (p 0.001) the proliferation-stimulating activity of 10-8 M 17-estradiol. Among the three drugs, tibolone exhibited the most potent inhibitory effect. Morphological detection and LDH determination revealed a strong cytotoxic activity of these three drugs. Extrapolations from these in vitro data suggest that the three drugs, alendronate, raloxifene and tibolone, do not increase the risk of cancer mediated via estrogen receptors and probably reduce the risk of developing breast cancer in estrogen users.


Keyword:

alendronate, estradiol, MCF-7 cells, raloxifene, tibolone, Estrogen replacement therapy, breast cancer




Download full paper (PDF File size: 217.16 KB.)





Vol.32
No.3-4
2005

See other volume

 


Vol.32
No.1-2
2005

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register



    Copyright © 2017
    Faculty of Pharmacy, Mahidol University, THAILAND